Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and ...

Prosecutors say the company filled unnecessary prescriptions that fueled the opioid epidemic. A spokesperson for CVS said the company admitted to no wrongdoing and “strongly disagreed” with the case’s ...

In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein ...

Part of a wave of young biotechs employing AI to accelerate research, the company claimed in regulatory filings that its approach has the potential to “disrupt legacy drug discovery paradigms.” ...

An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...

Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.

One lawyer involved noted how it's yet another example of Paragon and key investor Fairmount — which have helped transform ...

Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, ...

An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on ...

The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a ...

Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a ...